{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T13:35:31Z","timestamp":1793367331973,"version":"4.5.0"},"reference-count":15,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejso.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Surgical Oncology"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.ejso.2026.112026","type":"journal-article","created":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T06:56:24Z","timestamp":1784789784000},"page":"112026","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Preoperative chemoimmunotherapy vs chemoradiotherapy in cT4 ESCC: a multicenter retrospective study"],"prefix":"10.1016","volume":"52","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-8702-9393","authenticated-orcid":false,"given":"Kanghua","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-2239-7383","authenticated-orcid":false,"given":"Chang","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-7720-962X","authenticated-orcid":false,"given":"Xiaofang","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-0783-1039","authenticated-orcid":false,"given":"Chenglong","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5086-5334","authenticated-orcid":false,"given":"Zhigang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guoqing","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiangnan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.ejso.2026.112026_bib1","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"issue":"18","key":"10.1016\/j.ejso.2026.112026_bib2","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1200\/JCO.20.03614","article-title":"Ten-year outcome of neoadjuvant chemoradiotherapy plus surgery for esophageal cancer: the randomized controlled CROSS trial","volume":"39","author":"Eyck","year":"2021","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1016\/j.ejso.2026.112026_bib3","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1001\/jamasurg.2021.2373","article-title":"Long-term efficacy of neoadjuvant chemoradiotherapy plus surgery for the treatment of locally advanced esophageal squamous cell carcinoma: the NEOCRTEC50 10 randomized clinical trial","volume":"156","author":"Yang","year":"2021","journal-title":"JAMA Surg"},{"issue":"2","key":"10.1016\/j.ejso.2026.112026_bib4","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1046\/j.1442-2050.2003.00304.x","article-title":"Resection surgery with neoadjuvant chemoradiotherapy improves outcomes of patients with T4 esophageal carcinoma","volume":"16","author":"Noguchi","year":"2003","journal-title":"Dis Esophagus"},{"issue":"2","key":"10.1016\/j.ejso.2026.112026_bib5","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1245\/s10434-019-07654-8","article-title":"A 3-Year overall survival update from a phase 2 study of chemoselection with DCF and subsequent conversion surgery for locally advanced unresectable esophageal cancer","volume":"27","author":"Yokota","year":"2020","journal-title":"Ann Surg Oncol"},{"issue":"3","key":"10.1016\/j.ejso.2026.112026_bib6","doi-asserted-by":"crossref","DOI":"10.1093\/dote\/doy080","article-title":"Neoadjuvant chemotherapy with irinotecan and nedaplatin in a single cycle followed by esophagectomy on cT4 resectable esophageal squamous cell carcinoma: a prospective nonrandomized trial for short-term outcomes","volume":"32","author":"Tian","year":"2019","journal-title":"Dis Esophagus"},{"issue":"2","key":"10.1016\/j.ejso.2026.112026_bib7","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.annonc.2022.10.508","article-title":"Neoadjuvant chemoradiotherapy versus neoadjuvant chemotherapy followed by minimally invasive esophagectomy for locally advanced esophageal squamous cell carcinoma: a prospective multicenter randomized clinical trial","volume":"34","author":"Tang","year":"2023","journal-title":"Ann Oncol"},{"issue":"10447","key":"10.1016\/j.ejso.2026.112026_bib8","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/S0140-6736(24)00745-1","article-title":"Doublet chemotherapy, triplet chemotherapy, or doublet chemotherapy combined with radiotherapy as neoadjuvant treatment for locally advanced oesophageal cancer (JCOG1109 NExT): a randomised, controlled, open-label, phase 3 trial","volume":"404","author":"Kato","year":"2024","journal-title":"Lancet"},{"issue":"10302","key":"10.1016\/j.ejso.2026.112026_bib9","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/S0140-6736(21)01234-4","article-title":"Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study","volume":"398","author":"Sun","year":"2021","journal-title":"Lancet"},{"issue":"10294","key":"10.1016\/j.ejso.2026.112026_bib10","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S0140-6736(21)00797-2","article-title":"First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial","volume":"398","author":"Janjigian","year":"2021","journal-title":"Lancet"},{"issue":"10","key":"10.1016\/j.ejso.2026.112026_bib11","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1001\/jama.2021.12836","article-title":"Effect of camrelizumab vs placebo added to chemotherapy on survival and progression-free survival in patients with advanced or metastatic esophageal squamous cell carcinoma: the ESCORT-1st randomized clinical trial","volume":"326","author":"Luo","year":"2021","journal-title":"JAMA"},{"issue":"5","key":"10.1016\/j.ejso.2026.112026_bib12","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/S1470-2045(23)00108-0","article-title":"Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first-line treatment for advanced or metastatic oesophageal squamous cell carcinoma (RATIONALE-306): a global, randomised, placebo-controlled, phase 3 study","volume":"24","author":"Xu","year":"2023","journal-title":"Lancet Oncol"},{"issue":"5","key":"10.1016\/j.ejso.2026.112026_bib13","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1001\/jamasurg.2025.0220","article-title":"Neoadjuvant chemoradiotherapy vs chemoimmunotherapy for esophageal squamous cell carcinoma","volume":"160","author":"Guo","year":"2025","journal-title":"JAMA Surg"},{"issue":"1","key":"10.1016\/j.ejso.2026.112026_bib14","doi-asserted-by":"crossref","first-page":"155","DOI":"10.3390\/cancers18010155","article-title":"Three-year outcomes of neoadjuvant chemoimmunotherapy vs. neoadjuvant chemoradiotherapy in resectable esophageal cancer: a multicenter retrospective Study","volume":"18","author":"Deng","year":"2026","journal-title":"Cancers"},{"issue":"13","key":"10.1016\/j.ejso.2026.112026_bib15","doi-asserted-by":"crossref","first-page":"9321","DOI":"10.1245\/s10434-024-16033-x","article-title":"Induction therapy of Tislelizumab combined with Cisplatin and 5-Fluorouracil and subsequent conversion surgery in patients with unresectable advanced esophageal squamous cell carcinoma: a phase 2, single center study","volume":"31","author":"Xu","year":"2024","journal-title":"Ann Surg Oncol"}],"container-title":["European Journal of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0748798326006451?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0748798326006451?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T12:46:27Z","timestamp":1793364387000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0748798326006451"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":15,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["S0748798326006451"],"URL":"https:\/\/doi.org\/10.1016\/j.ejso.2026.112026","relation":{},"ISSN":["0748-7983"],"issn-type":[{"value":"0748-7983","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Preoperative chemoimmunotherapy vs chemoradiotherapy in cT4 ESCC: a multicenter retrospective study","name":"articletitle","label":"Article Title"},{"value":"European Journal of Surgical Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejso.2026.112026","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Ltd, BASO ~ The Association for Cancer Surgery, and the European Society of Surgical Oncology. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"112026"}}